Viking Therapeutics (NASDAQ: VKTX): The Next Obesity Catalyst May Be About Staying on Therapy

Key Highlights

• Phase 3 enrollment for injectable VK2735 is complete, with maintenance dosing data expected later this quarter.
• Oral Phase 3 development remains on track to begin in the fourth quarter of 2026.
• Viking is expanding beyond GLP-1/GIP with a new amylin receptor agonist entering the clinic.
• Cash of approximately $502 million is expected to fund operations into 2028 and through completion of ongoing Phase 3 obesity studies.

As obesity drug development matures, the conversation is beginning to shift. Early competition focused on how much weight patients could lose. The next competitive advantage may come from how well companies help patients maintain those results over the long term.

That theme was central to Viking Therapeutics’ (NASDAQ: VKTX) second-quarter update. While the company confirmed that its Phase 3 VANQUISH studies evaluating injectable VK2735 remain fully enrolled and on schedule, management also highlighted an increasingly differentiated part of its strategy: maintenance dosing. Data from a dedicated study evaluating weekly, every-other-week and monthly dosing regimens are expected later this quarter.

Viking continues advancing both injectable and oral formulations of VK2735. The oral Phase 3 program remains on track to begin in the fourth quarter of 2026, positioning the company to potentially compete across both formulations if development continues successfully.

Beyond VK2735, Viking is broadening its obesity pipeline with VK3019, a dual amylin and calcitonin receptor agonist now in Phase 1 development. The program reflects growing industry interest in combination approaches that could improve efficacy, durability or tolerability over time.

Financially, Viking ended the quarter with approximately $502 million in cash, cash equivalents and short-term investments, providing expected funding into 2028 and through completion of the company’s ongoing Phase 3 obesity studies.

For investors, the next catalyst may not simply be another weight-loss number. Maintenance dosing has become one of the most closely watched questions in obesity medicine, with clinicians increasingly focused on how patients remain on therapy after achieving initial weight loss. Viking’s upcoming data could provide an early look at whether more flexible dosing schedules become another point of differentiation in an increasingly competitive obesity market.